Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMO-103 in Advanced High-Grade Osteosarcoma
2024-510987-22-00Phase 2Suspended
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OMO-103 in osteosarcoma (OS), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Progression-free survival rate at 16 weeks. Started Sep 2024; status: suspended.
02
Drugs
OMO-103
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2024-510987-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510987-22-00.